Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
---|
12/07/2006 | US20060275260 Use of imatinib to treat liver disorders and viral infections |
12/07/2006 | US20060275259 Il-8-like proteins |
12/07/2006 | US20060275258 Interferon-alpha induced gene |
12/07/2006 | US20060275257 G-CSF Conjugates |
12/07/2006 | US20060275256 Inhibition of pathogenic agents including alpha6beta1 integrin receptor of alpha6beta4 integrin receptor at a surface |
12/07/2006 | US20060275255 NF-kappa B modulators; for protecting mammals from ionizing radiation sufficient to cause gastrointestinal syndrome or hematopoietic syndrome via administering recombinant flagellin |
12/07/2006 | US20060275254 covalently linked to a drug that is a physiologically active polypeptide through a non-peptide linker; nonimmunogenic; extended serum half-life of a drug while maintaining the in vivo activity |
12/07/2006 | US20060275252 Moiety is positioned between a water-soluble polymer and a reactive group; water soluble polymer such as polyethylene glycol containing a urethane linkage moiety for example, and a reactive group for conjugating with biodrugs |
12/07/2006 | US20060275251 Polymer complexes of glucuronoglucanes |
12/07/2006 | US20060275250 Reactive polymers and copolymers, method of their preparation and their use |
12/07/2006 | US20060275214 Methods of screening for anti-inflammatory drugs and use thereof |
12/07/2006 | US20060275213 Tumor targeting agents and uses thereof |
12/07/2006 | DE60118395T2 Pharmazeutische zusammensetzungen mit verzögerter freisetzung für die parenterale applikation von hydrophilen wirkstoffen Pharmaceutical compositions of active ingredients with controlled release for the parenteral administration of hydrophilic |
12/07/2006 | DE102005024836A1 Composition for treatment and prevention of bone tumors and metastases to bone, comprises microorganisms that carry a gene for abnormal bone sialoprotein, inducing an immune response |
12/07/2006 | CA2611155A1 Combination of hcv protease inhibitors with a surfactant |
12/07/2006 | CA2611145A1 Controlled-release formulation useful for treating disorders associated with hepatitis c virus |
12/07/2006 | CA2610786A1 High affinity melan-a t cell receptors |
12/07/2006 | CA2610782A1 Epo derivative-containing therapeutic agents for blood-related diseases |
12/07/2006 | CA2610691A1 Use of il-18bp isoforms for the treatment and/or prevention of neurological inflammatory diseases |
12/07/2006 | CA2610496A1 Synthetic peptide inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4 |
12/07/2006 | CA2610391A1 A method for optimized production of a recombinant form of tissue plasminogen activator |
12/07/2006 | CA2609951A1 Backbone cyclized melanocortin stimulating hormone (.alpha.s) analogs |
12/07/2006 | CA2609939A1 Fk 228 derivates as hdac inhibitors |
12/07/2006 | CA2609543A1 Mutant il-10 |
12/07/2006 | CA2609262A1 Anti-cd14 antibody fusion protein |
12/07/2006 | CA2609221A1 A peptide ligand to impair cancer cell migration |
12/07/2006 | CA2608504A1 Inhibition of neuronal damage |
12/07/2006 | CA2607701A1 Cell nucleus-entering compositions |
12/06/2006 | EP1728865A1 Treatment of cervical cancer |
12/06/2006 | EP1728864A1 Monoclonal antibodies specific for different epitopes of human gp39 and methods for their use in diagnosis and therapy |
12/06/2006 | EP1728863A2 C-class oligonucleotide analogs with enhanced immunostimulatory potency |
12/06/2006 | EP1728802A2 ErbB3 antibodies |
12/06/2006 | EP1728800A1 Papilloma virus-like particles, fusion proteins and process for producing the same |
12/06/2006 | EP1728517A2 Methods for treating mammary gland disorders |
12/06/2006 | EP1728516A1 A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure |
12/06/2006 | EP1728515A1 Influenza virus-infection inhibitor |
12/06/2006 | EP1728506A1 Coenzyme q composition with long-term persistence in blood |
12/06/2006 | EP1728431A1 Use of proteases for decomposing allergens |
12/06/2006 | EP1728423A2 Transgenic animal model of neurodegenerative disorders |
12/06/2006 | EP1727915A2 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof |
12/06/2006 | EP1727901A2 Materials and methods for treatment of cancer |
12/06/2006 | EP1727833A1 Recombinant polypeptides of the members of the tnf ligand family and use thereof |
12/06/2006 | EP1727831A1 Genes and polypeptides relating to prostate cancers |
12/06/2006 | EP1727561A1 Lactalbumin for inhibiting angiogenesis |
12/06/2006 | EP1727560A2 Gastrointestinal proliferative factor and uses thereof |
12/06/2006 | EP1727559A1 Use of fgf-21 and a thiazolidinedione for treating type 2 diabetes |
12/06/2006 | EP1727558A1 Use of dmbt1 for capturing sulphate and phosphate group exposing agents |
12/06/2006 | EP1727557A1 Uses of galectin-2 |
12/06/2006 | EP1727556A2 Materials and methods for treatment of inflammatory and cell proliferation disorders |
12/06/2006 | EP1727553A2 Agent for substitution of blood plasma and a method of its production |
12/06/2006 | EP1727548A2 Use of carboxypeptidase g for combating antifolate toxicity |
12/06/2006 | EP1727546A2 Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad |
12/06/2006 | EP1727520A2 Method of preparation of mixed phase co-crystals with active agents |
12/06/2006 | EP1727440A1 Method of preparing a food ingredient and food product having angiotensin-i-converting enzyme inhibiting properties and products thus obtained |
12/06/2006 | EP1682571A4 A bidentate motif and methods of use |
12/06/2006 | EP1682570A4 A binding motif and methods of regulating cell function |
12/06/2006 | EP1629106A4 METHODS OF INDUCING THE EXPRESSION OF BONE MORPHOGENETIC PROTEINS (BMPs) AND TRANSFORMING GROWTH FACTOR-beta-PROTEINS (TGF-betas) IN CELLS |
12/06/2006 | EP1490096B1 Use of hydrogen peroxide producing enzyme for treatment of otitis media |
12/06/2006 | EP1487462A4 Preparations for topical skin use and treatment |
12/06/2006 | EP1480667B1 Compositions comprising pulmonary surfactants and a polymyxin having improved surface properties |
12/06/2006 | EP1477181B1 Method of stimulating growth and resistance to diseases of aquatic organisms |
12/06/2006 | EP1451587A4 Antigen panels and methods of using the same |
12/06/2006 | EP1430304B1 Method for diagnosing chronic inflammatory bowel diseases |
12/06/2006 | EP1385887A4 Repressors for hiv transcription and methods thereof |
12/06/2006 | EP1353688B1 Method and compositions for immunization with the pseudomonas v antigen |
12/06/2006 | EP1270577B1 Furoisoquinoline derivatives, process for producing the same and use thereof |
12/06/2006 | EP1221975B1 Polymer stabilized neuropeptides |
12/06/2006 | EP1218381B1 AMINO SUBSTITUTED PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES AND PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES |
12/06/2006 | EP1119360B1 Compositions for increasing intestinal absorption of fats |
12/06/2006 | EP1117685B1 Treatment of inflammatory disease |
12/06/2006 | EP1078001B1 Il-6 antagonist peptides |
12/06/2006 | EP1051204B1 Prostheses with associated growth factors |
12/06/2006 | EP1025226B1 Dna encoding a human proton-gated ion channel and uses thereof |
12/06/2006 | EP1007686B1 Tuberculosis vaccine |
12/06/2006 | EP0983346B1 Short peptides which selectively modulate the activity of serine/threonine kinases |
12/06/2006 | EP0969865B1 Mhc class ii antigen-presenting systems and methods for activating cd4?+ t cells |
12/06/2006 | EP0948334B1 Method of treating prostatic diseases using active vitamin d analogues |
12/06/2006 | EP0938503B1 Insulin c-peptides |
12/06/2006 | EP0837934B1 Human vascular endothelial growth factor 2 |
12/06/2006 | EP0812333B1 Bispecific antibody effective to treat b-cell lymphoma and cell line |
12/06/2006 | EP0740701B1 Mammalian monocyte chemoattractant protein receptors |
12/06/2006 | EP0688362B1 Cloning and recombinant production of vespid venom enzymes, such as phospholipase and hyaluronidase, and immunological therapies based thereon |
12/06/2006 | EP0644771B2 Erythropoietin drug delivery system |
12/06/2006 | CN1875104A Anti-angiogenic peptides from the N-terminus of endostatin |
12/06/2006 | CN1875032A Biological active peptides comprising isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine |
12/06/2006 | CN1874786A Botulinum toxin treatments of neurological and neuropsychiatric disorders |
12/06/2006 | CN1874784A Treatment of sinusitis related chronic facial pain and headache with botulinum toxin injections |
12/06/2006 | CN1874783A Agent against malignant neuroglia and agent against malignant neuroglia for animals |
12/06/2006 | CN1874782A RAGE-related methods and compositions for treating glomerular injury |
12/06/2006 | CN1874679A Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
12/06/2006 | CN1873020A Diagnosing suppressor gene RhoGDI2 of tumour transfe, and therapeutic methods |
12/06/2006 | CN1873018A Target gene CK1 alpha of new medication |
12/06/2006 | CN1873013A Recombinant adenoviral vector and methods of use |
12/06/2006 | CN1873005A Conjugated protein Tau of microtubule of earthworm, its coding gene, and application |
12/06/2006 | CN1873003A 真菌细胞壁合成基因 Fungal cell wall synthesis genes |
12/06/2006 | CN1873002A 真菌细胞壁合成基因 Fungal cell wall synthesis genes |
12/06/2006 | CN1872881A Long effective amalgamation protein of erythropoietin of human, preparing and purifying methods |
12/06/2006 | CN1872879A Anagonism active polypeptide of CXCR4 acceptor from inflammation protein of virus macrophage |
12/06/2006 | CN1872878A Jingzhao toxin V |
12/06/2006 | CN1872877A Idiosyncratic antigen protein, and antigen peptide of liver cancer orchis pellet |